Cantargia Publishes Interim Report for Third Quarter 2019
Cantargia Publishes Interim Report for Third Quarter 2019 |
[15-November-2019] |
STOCKHOLM, Nov. 15, 2019 /PRNewswire/ -- Cantargia AB's ("Cantargia") interim report for the period January until September 2019 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant events in the third quarter
Significant events after the end of the period
Financial information
Third quarter 2019
For further information, please contact Göran Forsberg, CEO This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on November 15, 2019. About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. Cantargia's other project, CANxx, is in the research phase and is aiming to develop a IL1RAP binding antibody optimised for the treatment of autoimmune and inflammatory diseases. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com. This information was brought to you by Cision http://news.cision.com The following files are available for download:
| ||||||||
Company Codes: Stockholm:CANTA, ISIN:SE0006371126, RICS:CANTA.ST |
© 2019 PR Newswire. All Rights Reserved.